Back to top
more

LivaNova (LIVN)

(Delayed Data from NSDQ)

$42.76 USD

42.76
1,076,939

+1.63 (3.96%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $42.77 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LivaNova (LIVN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

LivaNova (LIVN) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

LivaNova (LIVN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 62.50% and 9.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 133.33% and 6.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Tops Q4 Earnings Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 7.58% and -0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: LivaNova (LIVN) Q4 Earnings Expected to Decline

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 80.95% and 8.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: LivaNova (LIVN) Q3 Earnings Expected to Decline

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for August 4th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

LivaNova (LIVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 50.00% and 6.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Lags Q1 Earnings Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of -2.94% and 3.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Q4 Earnings Top Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 5.26% and -1.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Q3 Earnings Surpass Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Zacks Equity Research

Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

by Zacks Equity Research

LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

Zacks Equity Research

LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

by Zacks Equity Research

Solid growth in emerging markets is expected to be an added positive this earnings season.

Zacks Equity Research

Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LivaNova (LIVN) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of -10.34% and -0.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More

by Zacks Equity Research

Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.